Achaogen Company Profile (NASDAQ:AKAO)

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AKAO
  • CUSIP: N/A
  • Web:
  • Market Cap: $755.55 million
  • Outstanding Shares: 42,233,000
Average Prices:
  • 50 Day Moving Avg: $20.76
  • 200 Day Moving Avg: $22.15
  • 52 Week Range: $3.65 - $27.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.78
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: $35.51 million
  • Price / Sales: 21.28
  • Book Value: $4.23 per share
  • Price / Book: 4.23
  • EBIDTA: ($68,050,000.00)
  • Net Margins: -281.88%
  • Return on Equity: -86.24%
  • Return on Assets: -51.32%
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 8.37%
  • Quick Ratio: 8.37%
  • Average Volume: 842,178 shs.
  • Beta: 1.6
  • Short Ratio: 6.33

Frequently Asked Questions for Achaogen (NASDAQ:AKAO)

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen, Inc. (NASDAQ:AKAO) released its earnings results on Thursday, August, 3rd. The company reported ($0.78) EPS for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.18. The firm earned $1.30 million during the quarter, compared to the consensus estimate of $2.69 million. Achaogen had a negative net margin of 281.88% and a negative return on equity of 86.24%. The firm's revenue was down 85.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.87) EPS. View Achaogen's Earnings History.

Where is Achaogen's stock going? Where will Achaogen's stock price be in 2017?

9 analysts have issued twelve-month target prices for Achaogen's stock. Their predictions range from $10.00 to $30.00. On average, they anticipate Achaogen's share price to reach $25.75 in the next twelve months. View Analyst Ratings for Achaogen.

What are analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

  • 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (7/17/2017)
  • 2. Cowen and Company analysts commented, "We are assuming coverage of AKAO with an Outperform." (5/5/2017)
  • 3. Needham & Company LLC analysts commented, "Achaogen mgmt provided a 4Q16 corporate update yesterday. Company remains on track for plazomicin NDA submission 2H17. Details around manufacturing/ CMC were provided, including role for Pfizer McPherson facility in fill/ finish. An FDA Warning Letter was issued to Pfizer last month for matters unrelated to plazomicin at facility. We assume resolution is likely before PDUFA date in 2018. We await additional information on new oral beta-lactam/ BLI cUTI program (C-Scape), but believe commercial opportunity for oral drug in this indication is one of most attractive areas in antibiotic space." (3/15/2017)
  • 4. Aegis analysts commented, "Yesterday after market close, Achaogen announced fourth quarter results, reporting revenue of $10.7 mil vs. street consensus estimates of $12.4 mil and GAAP-EPS of $(1.04) vs. consensus of $(0.49). The EPS miss comes primarily from a $16.9 mil expense recorded in the fourth quarter related to changes in warrants and derivative liabilities that was associated with the capital raise completed in June, 2016. Achaogen is a clinical stage development company, as such we believe the financials are less important, milestones and catalysts tend to drive valuation for these types of companies." (3/15/2017)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:

  • Bryan E. Roberts Ph.D., Chairman of the Board
  • Kenneth J. Hillan, President, Chief Executive Officer, Director
  • Blake Wise, President, Chief Operating Officer
  • Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  • Lee Swem, Senior Vice President, Chief Scientific Officer
  • Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy
  • Janet Dorling, Chief Commercial Officer
  • John C. Doyle, Director
  • Halley E. Gilbert Esq., Director
  • Kent E. Lieginger, Director

Who owns Achaogen stock?

Achaogen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (14.55%), FMR LLC (12.64%), State Street Corp (3.97%), Vanguard Group Inc. (3.93%), Versant Venture Management LLC (3.57%) and TimesSquare Capital Management LLC (3.04%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Who sold Achaogen stock? Who is selling Achaogen stock?

Achaogen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, EAM Investors LLC, Sphera Funds Management LTD., Goldman Sachs Group Inc., Nicholas Investment Partners LP, AXA, Fiera Capital Corp and Ameriprise Financial Inc.. Company insiders that have sold Achaogen stock in the last year include Blake Wise, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Insider Buying and Selling for Achaogen.

Who bought Achaogen stock? Who is buying Achaogen stock?

Achaogen's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, TimesSquare Capital Management LLC, Franklin Resources Inc., Vanguard Group Inc., Northern Trust Corp, Artal Group S.A., Farallon Capital Management LLC and Tudor Investment Corp ET AL. View Insider Buying and Selling for Achaogen.

How do I buy Achaogen stock?

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of Achaogen stock can currently be purchased for approximately $17.89.

MarketBeat Community Rating for Achaogen (NASDAQ AKAO)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Achaogen (NASDAQ:AKAO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $25.75 (43.94% upside)

Analysts' Ratings History for Achaogen (NASDAQ:AKAO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Stifel NicolausReiterated RatingBuy$30.00HighView Rating Details
6/15/2017HC WainwrightInitiated CoverageBuy -> Buy$29.00MediumView Rating Details
5/15/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
4/24/2017WedbushReiterated RatingOutperform$28.00HighView Rating Details
3/30/2017AegisDowngradeBuy -> Hold$29.00LowView Rating Details
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00MediumView Rating Details
1/24/2017GuggenheimReiterated RatingBuy$30.00N/AView Rating Details
1/4/2017Leerink SwannInitiated CoverageOutperform$21.00N/AView Rating Details
9/26/2016SunTrust Banks, Inc.Reiterated RatingBuy$10.00N/AView Rating Details
(Data available from 8/17/2015 forward)


Earnings History for Achaogen (NASDAQ:AKAO)
Earnings by Quarter for Achaogen (NASDAQ:AKAO)
Earnings History by Quarter for Achaogen (NASDAQ AKAO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.60)($0.78)$2.69 million$1.30 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Achaogen (NASDAQ:AKAO)
2017 EPS Consensus Estimate: ($2.57)
2018 EPS Consensus Estimate: ($3.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.48)($0.54)
Q2 20174($0.71)($0.58)($0.66)
Q3 20174($0.88)($0.62)($0.70)
Q4 20174($0.86)($0.59)($0.68)
Q1 20181($0.63)($0.63)($0.63)
Q2 20181($0.69)($0.69)($0.69)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.91)($0.91)($0.91)
(Data provided by Zacks Investment Research)


Dividend History for Achaogen (NASDAQ:AKAO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Achaogen (NASDAQ:AKAO)
Insider Ownership Percentage: 13.80%
Institutional Ownership Percentage: 68.59%
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Tobin SchilkeCFOSell2,066$21.53$44,480.98View SEC Filing  
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Achaogen (NASDAQ:AKAO)
Latest Headlines for Achaogen (NASDAQ:AKAO)
DateHeadline logoAchaogen, Inc. (AKAO) Given Average Rating of "Buy" by Brokerages - August 15 at 6:50 AM logoAchaogen, Inc. (AKAO) Downgraded to "Strong Sell" at BidaskClub - August 12 at 3:58 PM logoAchaogen to Present at the Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release) - August 8 at 8:42 PM logoAchaogen to Present at the Wedbush PacGrow Healthcare Conference - August 8 at 8:42 PM logoStifel Nicolaus Reaffirms Buy Rating for Achaogen, Inc. (NASDAQ:AKAO) - August 5 at 11:34 AM logoBIOVERATIV INC (BIVV) vs. Achaogen (NASDAQ:AKAO) Head-To-Head Review - August 5 at 8:30 AM logoAchaogen, Inc. (NASDAQ:AKAO) Releases Earnings Results - August 4 at 4:20 PM logoEdited Transcript of AKAO earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 4 at 4:01 PM logoAchaogen reports 2Q loss - August 3 at 9:56 PM logoAchaogen, Inc. – Value Analysis (NASDAQ:AKAO) : August 4, 2017 - August 3 at 9:56 PM logoAchaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release) - August 3 at 4:54 PM logoAchaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update - August 3 at 4:54 PM logoAchaogen, Inc. (AKAO) Downgraded to "Sell" at BidaskClub - July 31 at 4:47 PM logoAchaogen, Inc. (NASDAQ:AKAO) to Release Earnings on Monday - July 31 at 8:05 AM logoQ2 2017 Earnings Forecast for Achaogen, Inc. (NASDAQ:AKAO) Issued By Wedbush - July 31 at 7:02 AM logoHow These Biotech Stocks are Performing? -- Intrexon, 22nd Century, Corcept Therapeutics, and Achaogen - PR Newswire (press release) - July 26 at 3:43 PM logoAchaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant ... - Nasdaq - July 25 at 3:35 PM logoAchaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant ... - Nasdaq - July 25 at 3:35 PM logoAchaogen, Inc. (AKAO) Expected to Post Quarterly Sales of $2.30 Million - July 22 at 9:14 AM logoAchaogen, Inc. (NASDAQ:AKAO) Receives Average Recommendation of "Buy" from Brokerages - July 21 at 7:40 AM logoAchaogen, Inc. (NASDAQ:AKAO) Expected to Post Earnings of -$0.63 Per Share - July 20 at 6:26 PM logoAchaogen, Inc. breached its 50 day moving average in a Bearish Manner : AKAO-US : July 20, 2017 - July 20 at 5:04 PM logoCritical Analysis: Cerulean Pharma (CERU) vs. Achaogen (NASDAQ:AKAO) - July 18 at 1:17 PM logoAchaogen, Inc. (AKAO) Rating Increased to Hold at Zacks Investment Research - July 17 at 8:26 PM logoShort Interest in Achaogen, Inc. (AKAO) Grows By 55.2% - July 14 at 7:20 AM logoAchaogen (AKAO) Names Dr. Karen Bernstein to its Board of Directors - - July 13 at 9:28 PM logoAchaogen, Inc. (NASDAQ:AKAO) Downgraded by Zacks Investment Research to Sell - July 11 at 9:38 PM logoAchaogen, Inc. (NASDAQ:AKAO) Upgraded at BidaskClub - July 8 at 8:58 PM logoETFs with exposure to Achaogen, Inc. : July 4, 2017 - July 4 at 5:36 PM logo$2.30 Million in Sales Expected for Achaogen, Inc. (AKAO) This Quarter - June 28 at 11:14 AM logoAchaogen, Inc. (AKAO) Expected to Announce Earnings of -$0.63 Per Share - June 26 at 2:22 PM logoAchaogen, Inc. (AKAO) Given Consensus Rating of "Buy" by Brokerages - June 26 at 8:00 AM logoAchaogen, Inc. breached its 50 day moving average in a Bullish Manner : AKAO-US : June 22, 2017 - June 22 at 12:23 PM logoAchaogen, Inc. (AKAO) Research Coverage Started at HC Wainwright - June 17 at 9:04 PM logoAchaogen, Inc. (AKAO) CFO Tobin Schilke Sells 2,066 Shares - June 14 at 10:48 PM logoAchaogen (AKAO) Highlights Data Demonstrating Potential of ... - - June 5 at 11:35 PM logoAchaogen Inc (AKAO) Expected to Announce Quarterly Sales of $2.33 Million - June 2 at 1:52 PM logoAchaogen Announces Closing of Public Offering - May 31 at 8:29 PM logoAchaogen Inc (AKAO) Expected to Announce Earnings of -$0.66 Per Share - May 31 at 10:30 AM logoAchaogen Inc (AKAO) Given Consensus Rating of "Buy" by Analysts - May 30 at 8:01 AM logoAchaogen, Inc. breached its 50 day moving average in a Bearish Manner : AKAO-US : May 26, 2017 - May 26 at 3:40 PM logoAchaogen (AKAO) Prices 5M Share Offering at $22.50/Sh - - May 26 at 1:53 AM logoAchaogen's Plazomicin Gets Breakthrough Therapy Designation - Nasdaq - May 24 at 3:24 PM logoAchaogen (AKAO) Commences 5M Share Offering of Common Stock - - May 24 at 7:07 AM logo4 Stocks Moving On Both News & Technicals - May 19 at 9:38 AM logoTop 4 Pharmaceutical Stocks for 2017 - May 19 at 9:38 AM logoAchaogen Inc (AKAO) Expected to Earn FY2017 Earnings of ($2.70) Per Share - May 11 at 11:42 AM logoQ2 2017 EPS Estimates for Achaogen Inc Cut by SunTrust Banks (AKAO) - May 11 at 9:26 AM logoAchaogen Inc Forecasted to Post Q2 2017 Earnings of ($0.71) Per Share (AKAO) - May 11 at 9:26 AM logoQ2 2017 Earnings Forecast for Achaogen Inc Issued By Wedbush (AKAO) - May 11 at 9:24 AM



Achaogen (AKAO) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by Staff